Nolan Visit 1: A 53-year-old man with poorly controlled diabetes and dyslipidemia

Managing patients with hyperglycemia and other risk factors
0.5 AMA PRA Category 1 Credit(s)™
Launch Date:
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Robert C. Stanton, MD

Robert C. Stanton, MD
Associate Professor of Medicine
Harvard Medical School
Chief of Nephrology
Joslin Diabetes Center
Boston, MA

Dr. Stanton is a Principal Investigator in the Section on Vascular Cell Biology and the Chief of the Nephrology Section at Joslin Clinic, as well as an Associate Professor of Medicine at Harvard Medical School.
He received his medical degree from Hahnemann Medical College in Philadelphia and completed residency training at the Oregon Health and Science University, where he was the Chief Resident in Internal Medicine. He completed his fellowship in Nephrology at Harvard Medical School and Brigham and Women's Hospital and postdoctoral training in Physiology at Tufts University School of Medicine.
Dr. Stanton's research is focused on an essential enzyme that plays a major role in regulating oxidative stress levels in all cells, glucose 6-phosphate dehydrogenase. His work is aimed at elucidating the basic cellular mechanisms underlying development of diabetic kidney disease, and, with collaborators, his work also focuses on the causes for death of pancreatic beta cells and causes of hypertension and cardiovascular disease.
Dr. Stanton also is very involved with teaching at all levels (student, resident, fellow, and faculty). He serves on many Harvard Medical School Committees and is co-director of the Human Systems Pathophysiology Course for second-year medical students at Harvard Medical School. He also is the Chairman of the Year 2 Harvard Medical School Year 2 Curriculum Organizational Committee as well as Chairman of the IRB at Joslin Diabetes Center. Dr. Stanton is an author of many original articles and chapters, and serves both in reviewer and in editorial positions for academic journals.

David Erani, MD

David Erani, MD
Director of Medical Programs
Strategic Initiatives
Joslin Diabetes Center
Boston, MA

Dr. David Erani has joined our team as Director of Medical Programs for the Joslin Affiliates network. He will also hold this same role in Healthcare Services.

David first came to Joslin 15 years ago as a fellow. A native New Yorker, after completing his fellowship, he returned to New York to join the staff of Bronx-Lebanon Hospital where he rose to the rank of Chief of Endocrinology, Diabetes, and Metabolism. In 2008, he was recruited to Diabetes America where he served as Chief Medical Officer of the company which operates diabetes centers throughout the state of Texas. For the past 18 months, he served as Medical Director of the Joslin Affiliate at Cypress Fairbanks Medical Center in Houston.

In Affiliated Programs, he will work with the Boston team to conduct annual and targeted site visits for Affiliates, and to develop our inpatient offering for Affiliates. He will share insights gained from his experience in a variety of clinical settings, including Joslin Diabetes Center, a South Bronx diabetes center, a multisite diabetes practice in Texas, and the Joslin Affiliate at Cypress Fairbanks Medical Center Hospital in Houston.

Fredrick Dunn, MD

Fredrick Dunn, MD  
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Dr. Dunn received his undergraduate degree from the University of Michigan and his medical degree from the University of Illinois at Chicago. He completed his residency in Internal Medicine and fellowship in Endocrinology and Metabolism at the University of Texas Southwestern Medical Center at Dallas. After finishing his training, Dr. Dunn joined Joslin Diabetes Center and the Harvard Medical School faculty. In 1986 he moved to Duke University Medical Center, where he established the Duke Lipid Clinic and was co-director of the Diabetes Management Service. In 1994, Dr. Dunn joined Merck & Co., Inc., as Senior Medical Director for the South Central Region, and was later promoted to Executive Director for Academic and Professional Affairs. In 2000, he moved to Novartis Pharmaceuticals Corp. as Vice-President & Global Head, Diabetes Clinical Research, and later moved to Tularik, Inc., in South San Francisco, CA, as Head, Clinical Research, Metabolism and Endocrinology. After the acquisition of Tularik by Amgen, Inc., Dr. Dunn returned to the University of Texas Southwestern Medical Center at Dallas where he is currently the Director of the Lipid and Diabetes Management Services and Medical Director of the Chronic Disease Management Program at the Dallas Veterans Affairs Medical Center. Dr. Dunn's research interests include diabetic dyslipidemia, intensive insulin therapy with implantable insulin pumps, and treatment of insulin-resistant diabetes. 
1. Demonstrate the ability to set individualized glycemic control goals 
2. Demonstrate the ability to design a glycemic control program using antidiabetes medications and/or insulin in a manner that balances underlying pathophysiology with patient-specific considerations 
3. Demonstrate the ability to recognize markers of increased risk for development of diabetes-related complications, and initiate office-based complication monitoring and early intervention programs